Safeguarding the gift of life


Harmonize transplant monitoring to protect a second chance in life

A patient’s journey does not stop at transplantation—protecting a donated organ or graft from rejection is key to the recipient’s success.

Post-transplant immunosuppressive regimens are essential for preventing organ rejection, but they can also put patients at risk of opportunistic infections.

Amongst others Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), and BK Virus (BKV) are associated with significant morbidity and mortality in transplant recipients.1

These infections can be introduced through the donor organ or re-activated after the operation. By regularly monitoring viral load, care teams can identify possible infections early and better decide on an appropriate management plan.

Transplant map

Standardization is the key to care


A transplant patient’s journey can span several healthcare facilities, including transplant centers that may be far away from the coordinated care of one’s local specialist. The use of different testing methodologies across various sites makes it difficult to compare viral load results, not to mention that values are not always reported in the World Health Organization (WHO) international standard for ease of commutability. 

Furthermore, faced with growing pressure to produce reliable results in short turnaround times, there’s the need to reduce testing complexity and look beyond laboratory developed tests. By offering a standardized workflow, laboratories can deliver more uniform results to enable better clinical decision-making. 

See why result standardization is important for patient follow-up


Chief Medical Officer at Roche Molecular Diagnostics, Alexandra Valsamkis, discusses the importance of standardized assays.

Standardized results can improve care

Establishing harmonization in post-transplant monitoring


To optimize viral load monitoring and elevate patient care, Roche offers the first FDA-cleared and approved molecular transplant portfolio - The cobas® CMV, cobas® EBV and cobas® BKV tests.

These critical transplant viral tests can run from a single patient sample on the fully automated cobas® 6800 and cobas® 8800 Systems, providing laboratories with trusted results quickly in a streamlined workflow. Ready-to-use reagents and controls are calibrated to WHO international standards, ensuring result comparison across healthcare institutions no matter where the tests are run.

With these latest additions, Roche now has a robust, comprehensive transplant portfolio spanning across serology, molecular and tissue diagnostics to enable confident decision making—all to help protect a second chance in life. 

Laboratory employee working in molecular laboratory

Contact your Roche representative to learn more about the new standard in post-transplant monitoring.

Form Successfully Submitted!
Thank you for your submission!



  1. Smith TF, Espy MJ, Mandrekar J, Jones MF, Cockerill FR, Patel R. Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients. Clin Infect Dis. 2007;45(8):1056-1061.